Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials

[1] Wu Z(2020)Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese center for disease control and prevention JAMA 323 1239-1242

[2] McGoogan JM(2020)Variation in US Hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic JAMA Intern Med 384 693-704

[3] Asch DA(2020)Long term outcomes of critically ill COVID-19 pneumonia patients: early learning Intensive Care Med 202 1460-1462

[4] Sheils NE(2021)Dexamethasone in hospitalized patients with Covid-19 N Engl J Med 2 e594-e602

[5] Islam MN(2020)Immunomodulators in COVID-19: two sides to every coin Am J Respir Crit Care Med 202 812-821

[6] Chen Y(2020)COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study Lancet Rheumatol 8 1233-1244

[7] Werner RM(2020)Characterization of the inflammatory response to severe COVID-19 illness Am J Respir Crit Care Med 339 b2700-926

[8] Buresh J(2020)Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Lancet Respir Med 366 l4898-3457

[9] Doshi JA(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 336 924-468

[10] McCue C(2019)RoB 2: a revised tool for assessing risk of bias in randomised trials BMJ 25 3443-40

[1] Wu Z(2020)Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese center for disease control and prevention JAMA 323 1239-1242

[2] McGoogan JM(2020)Variation in US Hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic JAMA Intern Med 384 693-704

[3] Asch DA(2020)Long term outcomes of critically ill COVID-19 pneumonia patients: early learning Intensive Care Med 202 1460-1462

[4] Sheils NE(2021)Dexamethasone in hospitalized patients with Covid-19 N Engl J Med 2 e594-e602

[5] Islam MN(2020)Immunomodulators in COVID-19: two sides to every coin Am J Respir Crit Care Med 202 812-821

[6] Chen Y(2020)COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study Lancet Rheumatol 8 1233-1244

[7] Werner RM(2020)Characterization of the inflammatory response to severe COVID-19 illness Am J Respir Crit Care Med 339 b2700-926

[8] Buresh J(2020)Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Lancet Respir Med 366 l4898-3457

[9] Doshi JA(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 336 924-468

[10] McCue C(2019)RoB 2: a revised tool for assessing risk of bias in randomised trials BMJ 25 3443-40